Zobrazeno 1 - 10
of 45
pro vyhledávání: '"U. T. Hacker"'
Autor:
U T, Hacker, D, Hasenclever, R, Baber, N, Linder, H, Busse, R, Obermannova, L, Zdrazilova-Dubska, D, Valik, F, Lordick
Publikováno v:
Annals of Oncology. 33:685-692
Sarcopenia represents an established adverse prognostic factor in cancer patients. Consequently, different means to counteract sarcopenia have been proposed to improve cancer treatment. Computed tomography (CT)-based measurements, also labor intensiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0772a15adeba8d3ff9b20e34235be6a8
https://doi.org/10.1016/j.annonc.2022.03.274
https://doi.org/10.1016/j.annonc.2022.03.274
Publikováno v:
Gastroenterology Research and Practice, Vol 2016 (2016)
Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit. We synthesized the available evidence in a meta-analysis. Patients and Methods. We conducted a meta-analysis of stu
Externí odkaz:
https://doaj.org/article/52165bf43beb4fa5ad16dbde66ee271a
Autor:
H, Büning, U T, Hacker
Publikováno v:
Advances in experimental medicine and biology. 917
Angiogenesis plays a pivotal role in malignant, ischemic, inflammatory, infectious and immune disorders. The increasing molecular understanding of angiogenic processes fostered the development of strategies to induce or inhibit angiogenesis for thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e03d8a42100795949c9dc2119cca5084
https://pubmed.ncbi.nlm.nih.gov/27236560
https://pubmed.ncbi.nlm.nih.gov/27236560
Autor:
I. Burkholder, U. Ronellenfitsch, Stefan Kubicka, Alfredo Falcone, R.D. Hofheinz, U. T. Hacker
Publikováno v:
Gastroenterology Research and Practice, Vol 2016 (2016)
Gastroenterology Research and Practice
Gastroenterology Research and Practice
Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit. We synthesized the available evidence in a meta-analysis.Patients and Methods. We conducted a meta-analysis of stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aab3e603e0474b6d7355d8e54b6f0c5
http://hdl.handle.net/11568/828180
http://hdl.handle.net/11568/828180
Autor:
U. T. Hacker, H. Büning
Publikováno v:
Advances in Experimental Medicine and Biology ISBN: 9783319328041
Protein Targeting Compounds ISBN: 9783319224725
Protein Targeting Compounds ISBN: 9783319224725
Angiogenesis plays a pivotal role in malignant, ischemic, inflammatory, infectious and immune disorders. The increasing molecular understanding of angiogenic processes fostered the development of strategies to induce or inhibit angiogenesis for thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::113ef7954d64318d20f6d944c21ba8b5
https://doi.org/10.1007/978-3-319-32805-8_12
https://doi.org/10.1007/978-3-319-32805-8_12
Publikováno v:
memo - Magazine of European Medical Oncology. 4:75-78
Systemic treatment of metastatic colorectal cancer is increasingly being tailored towards the individual clinical situation of the patient. In particular, the k-ras mutation status as a predictive marker for the therapeutic efficacy of epidermal grow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efb5c912b115bffe77ae1dd2720dd90b
https://doi.org/10.1007/s12254-011-0265-4
https://doi.org/10.1007/s12254-011-0265-4
Autor:
R. Ehrenberg, Klaus Mross, C.-H. Köhne, Gunnar Folprecht, Susanne Hamann, J. Kuhlmann, Martin Kornacker, Dirk Strumberg, Beate Schultheis, R. Fischer, O. Boix, Jürgen Krauss, John Lettieri, U. T. Hacker
Publikováno v:
Annals of Oncology
Background Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan. The multitargeted kinase inhibitor, regorafenib, was combined with chemotherapy as first- or second-line treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e98870106b09414d9ae88a0c2b34acf8
https://pubmed.ncbi.nlm.nih.gov/23493136
https://pubmed.ncbi.nlm.nih.gov/23493136
[Recent results of research on cancer of the colon, gastric cancer, sarcoma and bronchial carcinoma]
Publikováno v:
Deutsche medizinische Wochenschrift (1946). 136(5)
In patients up to 70 years of age with colon carcinoma stage III adjuvant chemotherapy with infusions of fluorouracil (5-FU) or oral capecitabine combined with oxaliplatin should be the standard method. A new standard for the palliative treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c9838b9394b596cd99664ba86e68650a
https://pubmed.ncbi.nlm.nih.gov/21271476
https://pubmed.ncbi.nlm.nih.gov/21271476
Autor:
U T, Hacker, C, Bidlingmaier, M, Gomolka, E, Keller, A, Eigler, G, Hartmann, C, Folwaczny, H, Fricke, E, Albert, K, Loeschke, S, Endres
Publikováno v:
European journal of clinical investigation. 28(3)
Interleukin 1 (IL-1) and its physiological antagonist interleukin-1 receptor antagonist (IL-1 ra) play a crucial role in the pathogenesis of inflammatory bowel disease. Polymorphisms in the genes coding for these cytokines, the restriction enzyme Taq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::77f41849a86164a99366e77c99412b98
https://pubmed.ncbi.nlm.nih.gov/9568467
https://pubmed.ncbi.nlm.nih.gov/9568467
Autor:
Christian Mattonet, H. Backes, Karin Toepelt, Thomas Elter, Matthias Scheffler, Carsten Kobe, Lucia Nogova, U. T. Hacker, Ildiko Katay, Nadia Harbeck, Peter Mallmann, Markus Dietlein, N. Muthen, Uwe Fuhr, Irini Papachristou, Kerstin Rhiem, Martin L. Sos, Roland Schnell, Juergen Wolf, M. Reiser
Publikováno v:
Journal of Clinical Oncology. 29:e13613-e13613
e13613 Background: The combination of the multi-kinase inhibitor sorafenib (S) and the mTOR inhibitor everolimus (E) may increase anti-tumor efficacy by dual inhibition of key nodules of signaling ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55a2089a97ae296a7e29db685379581e
https://doi.org/10.1200/jco.2011.29.15_suppl.e13613
https://doi.org/10.1200/jco.2011.29.15_suppl.e13613